Obesity is an important risk factor for severe asthma exacerbations, which are mainly caused by respiratory infections. Dietary fatty acids, which are increased systemically in obese patients and are further increased after high-fat meals, affect the innate immune system and may contribute to dysfunctional immune responses to respiratory infection. In this study we investigated the effects of dietary fatty acids on immune responses to respiratory infection in pulmonary fibroblasts and a bronchial epithelial cell line (BEAS-2B). Cells were challenged with BSA-conjugated fatty acids (v-6 polyunsaturated fatty acids [PUFAs], v-3 PUFAs, or saturated fatty acids [SFAs]) 1/2 the viral mimic polyinosinic:polycytidylic acid (poly[I:C]) or bacterial compound lipoteichoic acid (LTA), and release of proinflammatory cytokines was measured. In both cell types, challenge with arachidonic acid (AA) (v-6 PUFA) and poly(I:C) or LTA led to substantially greater IL-6 and CXCL8 release than either challenge alone, demonstrating synergy. In epithelial cells, palmitic acid (SFA) combined with poly(I:C) also led to greater IL-6 release. The underlying signaling pathways of AA and poly(I:C)-or LTA-induced cytokine release were examined using specific signaling inhibitors and IB. Cytokine production in pulmonary fibroblasts was prostaglandin dependent, and synergistic upregulation occurred via p38 mitogenactivated protein kinase signaling, whereas cytokine production in bronchial epithelial cell lines was mainly mediated through JNK and p38 mitogen-activated protein kinase signaling. We confirmed these findings using rhinovirus infection, demonstrating that AA enhances rhinovirus-induced cytokine release. This study suggests that during respiratory infection, increased levels of dietary v-6 PUFAs and SFAs may lead to more severe airway inflammation and may contribute to and/or increase the severity of asthma exacerbations.
More than 2 billion people around the world are overweight or obese with a body mass index (BMI) of 25 kg/m 2 or more (1) . This global epidemic is associated with many chronic diseases, including asthma. A number of epidemiological studies show that obesity is an important risk factor for asthma development, increasing the risk by 2.7-fold compared with normal body weight (2) . However, the underlying mechanisms are still poorly understood.
Clinical studies suggest that asthma in obese individuals differs from the classical phenotype of the disease. The obese asthma phenotype is characterized by greater severity, poorer control and quality of life, and lack of atopy, with neutrophilic inflammation being specifically reported in obese women (2) (3) (4) (5) . Obesity also increases the risk of exacerbations and obese patients are almost five times more likely to be hospitalized for asthma exacerbations than lean patients (3, 6, 7) . A higher BMI appears to particularly increase the risk of autumn/winter exacerbations in more severe forms of asthma (6) .
The major cause of asthma exacerbations is respiratory infection with rhinovirus (RV), which accounts for up to 80% of all exacerbations (8) . Viral-induced exacerbations in asthma are associated with increased levels of IL-6, the neutrophil chemoattractant CXCL8, and neutrophilic inflammation (9, 10) . Some studies have reported that bacterial infection is also related to asthma exacerbations (11, 12) ; however, this relationship is less evident. The impact of obesity on immune responses to infections is not clear, but obesity is associated with more severe outcomes after respiratory infection (13, 14) . Several studies showed associations between obesity and hospitalization and mortality after infection with pandemic influenza A/H1N1 2009 (15, 16) . A recent study by Campitelli and colleagues showed that obesity increases the risk of outpatient visits after respiratory infection compared with a normal body weight (14) .
The innate immune system is the first line of defense against pathogens and its aim is to rapidly clear the body of pathogens. To do so, the innate immune system triggers an immediate inflammatory response that induces migration and activation of immune cells into infected sites. However, an excessive inflammatory response may induce greater tissue damage than that caused by pathogens and can contribute to the cause and severity of exacerbations (8) .
Obesity is the result of a continuous overconsumption of nutrients. The Western diet contributes to obesity, being rich in saturated fatty acids (SFAs) and v-6 polyunsaturated fatty acids (PUFAs) and low in v-3 PUFAs (17) . It has been shown that the consumption of high-fat meals leads to increased levels of circulating fatty acids and modulates the innate immune system, as shown by increases in the levels of CXCL8 as well as the proportion of neutrophils in the circulation and sputum (18, 19) . Obesity itself is also associated with increased fatty acid levels (20) . The serum levels of SFAs and v-6 PUFAs are substantially higher than those of v-3 PUFAs (21-23). v-6 PUFAs and SFAs have predominantly been associated with proinflammatory effects, and current evidence suggests that SFAs promote inflammation through activation of a family of receptors involved in innate immunity, known as Toll-like receptors (TLRs) (24) . Several studies have suggested that v-3 PUFAs have antiinflammatory and immunosuppressive properties and may be beneficial in treating infectious diseases. v-3 and v-6 PUFAs act as bioactive molecules that are metabolized by cyclooxygenase (COX) and lipoxygenase into prostaglandins (PGs) and leukotrienes, respectively, which have potential anti-and proinflammatory actions of their own (25) .
An emerging hypothesis to explain why obese patients have more frequent and severe asthma exacerbations is dysfunctional innate immune responses to viral and/or bacterial respiratory infections. Increased levels of dietary fatty acids could potentially contribute to these dysfunctional immune responses.
The bronchial epithelium has always been considered as the primary site of infection. However, in vivo evidence shows that infection also occurs in submucosal cells, including pulmonary fibroblasts (26) . In this study we investigated the effect of dietary fatty acids on primary human pulmonary fibroblasts (HPFs) and a bronchial epithelial cell line (BEAS-2B) in vitro, and specifically examined the possible enhancement of respiratory infection by measuring the release of inflammatory mediators involved in immune responses against infection.
Methods

Cell Culture
HPFs were isolated from the parenchyma of lungs from patients undergoing lung transplantation or lung resection for thoracic malignancies, as previously described (27) . Ethical approval for all experiments involving the use of human lung tissue was provided by the Sydney South West Area Health Service, and written informed consent was obtained. Table 1 shows the patient demographics. We also used the bronchial cell line BEAS-2B (ATCC). Details regarding the methods used for culture of HPFs and BEAS-2B are provided in the data supplement. Aldrich) were prepared in 100% ethanol and stored at 220 8 C. Working watersoluble solutions of 10 mM were generated by incubating the fatty acids in 10% endotoxin and fatty acid-free BSA (Sigma Aldrich) as previously described by Gupta and colleagues (28) .
Treatment of Cells
The cells were challenged with DHA, EPA, ALA, PA, or AA (100 mM) or vehicle (ethanol/BSA/cell culture medium) 4 hours before stimulation with or without the viral mimic polyinosinic:polycytidylic acid (poly[I:C]) (10 mg/ml) or the bacterial compound lipoteichoic acid (LTA) (10 mg/ml) (Sigma Aldrich). All cells were incubated at 37 8 C with 5% CO 2 for 24 hours.
Determination of IL-6, CXCL8, Granulocyte-Macrophage ColonyStimulating Factor, and CCL5 Levels
The levels of supernatant IL-6, CXCL8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and chemokine (C-C motif) ligand 5 (CCL5) were measured using commercial ELISA kits (R&D Systems) according to the manufacturer's instructions.
Western Blotting
Total protein concentrations were obtained using a bicinchoninic acid assay (SigmaAldrich) according to the manufacturer's instructions. Cell lysates (10 mg) were separated by SDS-PAGE on 10% gels and transferred to polyvinylidene fluoride membranes. The membranes were incubated with rabbit monoclonal antibodies against total and phosphorylated NF-kB p65, p38 mitogen-activated protein kinase (MAPK), or stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) (all 1:1,000; Cell Signaling Technology) and anti-mouse GAPDH (1:5,000; Merck Millipore). Primary antibodies were detected with goat antirabbit or rabbit anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibodies (DAKO) and visualized by enhanced chemiluminescence (Image Station 4000MM; Kodak Digital Science). GAPDH served as the loading control. Details regarding the methods used are provided in the data supplement.
Signaling Pathway Inhibition
HPFs and BEAS-2Bs were treated with inhibitors of p38 MAPK (SB239063, 3 mM, IC 50 = 44 nM) (Tocris), JNK (SP600125, 10 mM, IC 50 = 40 nM for JNK-1 and JNK-2, and 90 nM for JNK-3) (Calbiochem), COX (indomethacin, 10 mM, IC 50 = 0.23 mM for COX-1 and IC 50 = 0.63 mM for COX-2) (Sigma), and NF-kB (BAY-117082, 10 mM, IC 50 = 10 mM) (Sigma) for 1 hour before stimulation with AA (100 mM) with or without poly(I:C) (10 mg/ml) or LTA (10 mg/ml).
RV Infection
Major group human RV serotype-16 (RV16) was a kind gift from Prof. S. Johnston (Imperial College UK).
RV16 was grown in HeLa cells and infectivity titer was determined using a titration assay as previously described (29, 30) . HPFs were unstimulated or treated with AA (100 mM) 4 hours before infection with or without live RV16 at a multiplicity of infection (MOI) of 1. Plates were incubated at 37 8 C with 5% CO 2 for 24 hours. Definition of abbreviations: ALA = a-linolenic acid; BOS = bronchiolitis obliterans syndrome; COPD = chronic obstructive pulmonary disease; EPA = eicosapentaenoic acid; IPF = idiopathic pulmonary fibrosis; F = female; M = male; NSCLC = non-small cell lung carcinoma; PAH = pulmonary arterial hypertension; PUFAs = polyunsaturated fatty acids; RV16 = human rhinovirus 16.
Statistical Analysis
Statistical analysis was conducted using GraphPad Prism version 7 software.
Comparisons of the data were performed by one-way ANOVA with repeated measures followed by a Bonferroni post test when appropriate unless otherwise specified. A P value of ,0.05 was considered significant.
Results
Stimulation with AA and poly(I:C) Leads to Greater Cytokine Release from Fibroblasts
To assess whether dietary fatty acids modulate the response to viral infection, HPFs were challenged with 100 mM of DHA, PA, or AA before stimulation with poly(I:C) (10 mg/ml), and IL-6, CXCL8, GM-CSF, and CCL5 release was measured. AA alone, but not DHA or PA, induced IL-6 and CXCL8 release (n = 11, P , 0.05) ( Figure 1 ). poly(I:C) alone also induced IL-6 and CXCL8 release (n = 11, P , 0.05).
Challenge with the combination of AA and poly(I:C) resulted in substantially greater IL-6 and CXCL8 release than AA alone (n = 11, P , 0.01) ( Figures 1A and 1B) . The effect of the combination of AA with poly(I:C) on IL-6 and CXCL8 release was greater than the sum of the individual effects of AA and poly(I:C), demonstrating a synergistic effect. There was no interaction between DHA or PA and poly(I:C) on IL-6 and CXCL8 release. None of the treatments induced GM-CSF release from the HPFs (data not shown). CCL5 was induced upon poly(I:C) challenge and, interestingly, AA and DHA suppressed poly(I:C)-induced CCL5 release (n = 5-8, P , 0.05) ( Figures  1C and 1F ).
Stimulation with AA and LTA Leads to Greater Cytokine Release from Fibroblasts
To evaluate whether there is an interaction between dietary fatty acids and bacterial infection, HPFs were treated with dietary fatty acids before stimulation with LTA (10 mg/ml). LTA alone did not induce IL-6 or CXCL8 release ( Figure 2 ). However, release of both IL-6 and CXCL8 (n = 11, P , 0.05) was greater upon challenge with the combination of AA and LTA than with AA alone (Figures 2A and 2B ), also demonstrating synergistic effects. Again, there was no interaction between DHA or PA and LTA. In addition, there was no induction of GM-CSF or CCL5 with any of these treatments (data not shown).
v-3 PUFAs Do Not Suppress Combined AA and poly(I:C)-induced Cytokine Release
The v-3 PUFA DHA did not affect poly(I:C)-induced IL-6 and CXCL8 release in HPFs. To confirm that v-3 PUFAs do not affect IL-6 and CXCL8 release, we investigated the effects of the other v-3 PUFAs, ALA and EPA, and found that these fatty acids also did not affect the response to poly(I:C) (see Figure  E1 in the data supplement). Because nutrients do not occur in isolation, and a healthy diet consists of v-3 PUFAs:v-6 PUFAs in a 1:4 ratio (31) To explore whether other structural lung cells respond similarly to HPFs, we repeated selected experiments in the bronchial epithelial cell line BEAS-2B. AA alone did not induce IL-6 or CXCL8 release from BEAS-2Bs; however, AA in combination with poly(I:C) resulted in greater IL-6 release (n = 6, P , 0.05) than poly(I:C) alone ( Figure 3A) , showing responses similar to those observed in HPFs. PA in combination with poly(I:C) also resulted in greater IL-6 release (n = 6, P , 0.05) than poly(I:C) alone ( Figure 3G ). DHA did not affect poly(I:C)-induced IL-6 or CXCL8 release, but suppressed poly(I:C)-induced CCL5 release (n = 7, P , 0.05) ( Figure 3F ). Furthermore, LTA alone did not induce cytokine release from BEAS-2BS. However, the combination of AA and LTA resulted in significant IL-6 and CXCL8 release (n = 6, P , 0.01) ( Figures 4A and 4B ). There was no interaction between DHA or PA and LTA ( Figures 4C-4F ). To investigate the mechanisms underlying the effects of AA-and combined AA and poly(I:C) or LTA-induced IL-6 and CXCL8 release in HPFs, we used protein IB to investigate the activation of three main signaling pathways (p38, NF-kB, and SAPK/JNK), all of which have been shown to play a role in PG-or infectionmediated inflammatory responses (32, 33) . Phosphorylation of p38 MAPK was increased after stimulation with AA alone (n = 8, P , 0.01) and in combination with poly(I:C) (P , 0.001) or LTA (P , 0.01), whereas poly(I:C) and LTA alone did not affect p38 MAPK phosphorylation ( Figure 5A ). The combination of AA and poly(I:C) led to greater phosphorylation of p38 MAPK than AA alone (n = 8, P , 0.05), indicating that hyperactivation of this pathway is the mechanism by which synergism occurs. NF-kB phosphorylation was increased upon challenge with poly(I:C) (n = 8, P , 0.01) and LTA alone (n = 8, P , 0.01), but not in combination with AA ( Figure 5B ). Phosphorylation of SAPK/JNK was increased upon challenge with AA in combination with poly(I:C) (n = 7, P , 0.05), but not with any other challenge ( Figure 5C ). Total p38 MAPK, NF-kB, and SAPK/JNK did not change with any treatment ( Figures 5D-5F ).
AA and poly(I:C) or LTA-induced Cytokine Release in Pulmonary Fibroblasts Is Mediated via p38 MAPK Signaling
To further investigate and confirm the mechanisms underlying the effects of AA-and combined AA and poly(I:C) or LTA-induced IL-6 and CXCL8 release, specific inhibitors were used to block p38 MAPK, JNK, and NF-kB activation. Inhibition of p38 MAPK suppressed IL-6 and CXCL8 (n = 9-14, P , 0.01) release induced by AA alone ( Figures 6A and 6B ) or the combinations of AA and poly(I:C) ( Figures 6E and 6F ) and AA and LTA ( Figures 6G and 6H ), but did not affect cytokine release induced by poly(I:C) alone. Inhibition of JNK attenuated IL-6 release induced by poly(I:C) alone (n = 10, P , 0.0001) ( Figure 6C ) and AA combined with poly(I:C) (n = 10, P , 0.01) ( Figure 6E ). Inhibition of NF-kB only suppressed IL-6 release induced by AA in combination with LTA (n = 14, P , 0.01) ( Figure 6G ).
Inhibition of COX Suppresses AA and poly(I:C) or LTA-induced Cytokine Release in Pulmonary Fibroblasts
AA is a bioactive molecule and is a precursor that is metabolized by COX to produce eicosanoids, including the PGs (25, 34 Figures 6G and 6H ) (n = 9-14, P , 0.01). However, indomethacin pretreatment did not affect cytokine release induced by poly(I:C) alone. The COX and p38 MAPK signaling pathways were the only two involved in both AA and poly(I:C)-as well as AA and LTA-induced IL-6 and IL-8 release.
AA and poly(I:C) or LTA-induced Cytokine Release in BEAS-2Bs Is Mainly Mediated by JNK and p38 MAPK Signaling
We also investigated the underlying mechanisms in BEAS-2Bs and found that phosphorylation of p38 MAPK was increased 30 minutes after stimulation with AA alone, and with AA in combination (A-C) Human primary pulmonary fibroblasts were unstimulated or challenged with the v-6 polyunsaturated fatty acid (PUFA) AA (n = 8-11) (patients), (D-F) the v-3 PUFA docosahexaenoic acid (DHA), (n = 5-9) (patients), or (G-I) the saturated fatty acid (SFA) palmitic acid (PA), (n = 3-9) (patients) in 0.1% BSA-Dulbecco's modified Eagle medium (BSA-DMEM, 100 mM) for 4 hours with or without the viral mimic poly(I:C) (10 mg/ml) for another 24 hours. Cell-free supernatants were collected and (A, D, and G) IL-6, (B, E, and H) CXCL8, or (C, F, and I) CCL5 release was measured using ELISA. All data are represented as mean 6 SEM. All challenges are compared with control, and challenges with poly(I:C) are compared with their respective challenge without poly(I:C) and challenge with poly(I:C) alone, using a one-way ANOVA with a Bonferroni post test. Significance is represented as *P , 0.05, **P , 0.01, ***P , 0.001, or ****P , 0.0001.
with poly(I:C) or LTA (n = 8, P , 0.05) ( Figure 7A ). NF-kB phosphorylation was increased upon challenge with poly(I:C) and LTA alone, and with AA in combination with poly(I:C) (n = 7, P , 0.05) ( Figure 7B ). Phosphorylation of SAPK/JNK was increased upon challenge with AA in combination with LTA (n = 7, P , 0.05) ( Figure 7C ).
In addition, inhibition of p38 MAPK or JNK suppressed IL-6 and CXCL8 release induced by poly(I:C) alone, AA in combination with poly(I:C), and AA in combination with LTA (n = 7, P , 0.05) (Figure 8 ). Inhibition of NF-kB suppressed IL-6 and CXCL8 release induced by AA in combination with poly(I:C) (n = 7, P , 0.05) (Figures 8A and 8B) , and CXCL8 release induced by poly(I:C) alone (P , 0.05) ( Figure 8D ). Inhibition of JNK resulted in the greatest suppression of combined AA and poly(I:C)-or LTA-induced IL-6 and CXCL8 release. Inhibition of COX did not suppress IL-6 or CXCL8 release in BEAS-2Bs. These results show that the responses in BEAS-2Bs are different from those in HPFs and are mediated through NF-kB, JNK, and p38 MAPK (but not COX) signaling, and suggest that JNK signaling is the dominant pathway.
Infection with Human RV16 Leads to Greater AA-induced Cytokine Release
To ensure that the results we obtained with pathogen components are reflective of a live infection, we next assessed whether the innate immune response to RV was modulated by AA. RV was chosen because it is the most common cause of common colds and has been shown to be a major cause of asthma exacerbations (8). Challenge with AA (100 mM) in combination with RV16 infection at an MOI of 1.0 resulted in substantially greater IL-6 and CXCL8 (P , 0.05) release than AA or RV alone from HPFs (n = 9) ( Figures 9A and 9B ) and BEAS-2Bs (n = 7) (replicates) (Figures 9C  and 9D ). The effect of the combination of AA with RV16 on IL-6 and CXCL8 release was greater than the sum of the individual effects of AA and RV16 in both cell types, demonstrating synergistic effects.
Discussion
Obese patients with asthma have more frequent and severe exacerbations, which may be a result of excess dietary fatty acids enhancing the innate immune response to viral and/or bacterial infection. This study is the first to examine the effects of dietary fatty acids in this context. This study demonstrates that the v-6 PUFA AA in combination with the viral mimic poly(I:C) results in greater IL-6 and CXCL8 release than either AA or poly(I:C) alone. Interestingly, the effect of the combination on cytokine release was substantially greater than the sum of the individual effects of AA and poly(I:C), Human primary pulmonary fibroblasts were unstimulated (control) or challenged with the v-6 PUFA AA (n = 11) (patients), (C and D) the v-3 PUFA DHA (n = 10) (patients), or (E and F) the SFA PA (n = 9) (patients) in 0.1% BSA-DMEM (100 mM) for 4 hours prior to 24 hours with or without the bacterial compound LTA (10 mg/ml). Cell-free supernatants were collected and (A, C, and E ) IL-6 and (B, D, and F) CXCL8 release was measured using ELISA. All data are represented as mean 6 SEM. All challenges are compared with control, and challenges with LTA are compared with their respective challenge without LTA and challenge with LTA alone, using a oneway ANOVA with a Bonferroni post test. Significance is represented as *P , 0.05 or ***P , 0.001.
which indicates that these effects are synergistic. We also examined the effects of dietary fatty acids on respiratory infection in epithelial cells. Interestingly, we found that epithelial cells were unresponsive to AA alone, but the combination with poly(I:C) resulted in synergistic cytokine release. In addition, PA enhanced poly(I:C)-induced cytokine release from epithelial cells. These results show that dietary fatty acids have different effects on different lung cells, and suggest that increased levels of AA and PA during viral infection may lead to more severe airway inflammation.
The current study focused mainly on the cytokines IL-6 and CXCL8, as these are crucial drivers of neutrophilic inflammation and are clinically important in both the pathogenesis of asthma and clinical outcomes in severe and obese asthma, including virus-induced exacerbations. However, multiple cytokines and chemokines are important for driving granulocyte recruitment and activation in asthma. We also measured CCL5 (RANTES) and GM-CSF release. There was no induction of GM-CSF in both cell types. Figure 3 . Greater IL-6 release was achieved with combined AA or PA and poly(I:C) challenge than with either alone in BEAS-2Bs. (A-C) The human bronchial epithelial cell line BEAS-2B was unstimulated (control) or challenged with the v-6 PUFA AA (n = 6-7) (replicates), (D-F) the v-3 PUFA DHA (n = 6-7) (replicates), or (G-I) the SFA PA (n = 6-7) (replicates) in 0.1% BSA-DMEM (100 mM) for 4 hours prior to 24 hours with or without the viral mimic poly(I:C) (10 mg/ml). Cell-free supernatants were collected and (A, D, and G) IL-6, (B, E, and H) CXCL8, and (C, F, and I) CCL5 release was measured using ELISA. All data are represented as mean 6 SEM. All challenges are compared with control, and challenges with poly(I:C) are compared with their respective challenge without poly(I:C) and challenge with poly(I:C) alone, using a one-way ANOVA with a Bonferroni post test. Significance is represented as *P , 0.05, **P , 0.01, or ***P , 0.001.
However, DHA reduced poly(I:C)-induced RANTES in HPFs and BEAS-2Bs. In addition, AA reduced poly(I:C)-induced RANTES in fibroblasts, but not BEAS-2Bs. We interpret these results as further evidence that the immune response in obese asthma is skewed toward neutrophilic inflammation. If GM-CSF induction had occurred, this would have been evidence of a granulocytic response, as it promotes the proliferation, differentiation, and activation of monocytes, neutrophils, eosinophils, and dendritic cells, and acts as a cofactor for superoxide production and degranulation (35, 36) . The suppression of CCL5 (RANTES) by AA further reinforces neutrophilic inflammation, as it typically recruits monocytes, T cells, and eosinophils, and has been associated with eosinophilic airway inflammation in asthma (37, 38) .
RV is the most common cause of virusinduced exacerbations in both children and adults with asthma (8, 39) . In the past, RV was considered as an upper-respiratory pathogen only. However, in vivo studies have conclusively shown that RV can also replicate in the lower airways (26, 40) and can infect submucosal cells, including pulmonary fibroblasts and airway smooth muscle cells. Other investigators and we have shown that RV infects primary pulmonary fibroblasts, inducing proinflammatory mediators such as IL-6 and CXCL8 (41, 42) . Fibroblasts are located within the airway submucosa where airway blood vessels are found, and therefore are directly exposed to constituents of tissue fluids (plasma), including dietary fatty acids, and are likely to be key cells in driving inflammatory responses to serumderived factors. As such, this study focused primarily on pulmonary fibroblasts.
Viruses activate the innate immune response through activation of the molecular pattern recognition receptors TLR3, TLR7, and TLR8 (43) via the activation of specific transcription factors, including NF-kB and AP-1. poly(I:C) is a synthetic analog of double-stranded RNA (dsRNA) and is known to activate TLR3 (44) . TLR7 and TLR8 detect singlestranded RNA, whereas TLR3 detects dsRNA, which occurs when single-stranded RNA viruses, including RV, replicate (43) . We used an agonist for TLR3 rather than TLR7 or TLR8 based on previous studies showing that RV induces cytokines via activation of TLR3, but not TLR7 or TLR8, in bronchial epithelial cells. Furthermore, we have previously shown that RV-induced cytokine release in fibroblasts is replication dependent (i.e., the cells detect and respond only to dsRNA) (41) . To confirm that AA increases RV-induced inflammation, we also assessed the response to AA in combination with RV16 infection. We found that challenge with AA in combination with RV16 infection resulted in substantially greater cytokine release The human bronchial epithelial cell line BEAS-2B was unstimulated (control) or challenged with the v-6 PUFA AA (n = 6) (replicates), (C and D) the v-3 PUFA DHA (n = 6) (replicates), or (E and F) the SFA PA (n = 6) (replicates) in 0.1% BSA-DMEM (100 mM) for 4 hours prior to 24 hours with or without the bacterial compound LTA (10 mg/ml). Cell-free supernatants were collected and (A, C, and E) IL-6 and (B, D, and F) CXCL8 release was measured using ELISA. All data are represented as mean 6 SEM. All challenges are compared with control, and challenges with LTA are compared with their respective challenge without LTA and challenge with LTA alone, using a one-way ANOVA with a Bonferroni post test. Significance is represented as *P , 0.05 or **P , 0.01. Figure 5 . Activation of p38 mitogen-activated protein kinase (MAPK), NF-kB, and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) upon challenge with AA and poly(I:C) or LTA. (A-C) Primary human pulmonary fibroblasts (n = 7-8) (patients) were unstimulated (control) or challenged with AA (100 mM), the viral mimic poly(I:C) (10 mg/ml), the bacterial compound LTA (10 mg/ml), AA (100 mM) in combination with poly(I:C) (1 ng/ml), or AA (100 mΜ) in combination with LTA for 30 minutes before whole-cell lysates were collected and p38 MAPK (A), NF-kB p65 (B), or JNK (C) phosphorylation was assessed by Western blotting. (D-F) Total p38 MAPK (D), NF-kB p65 (E), or SAPK/JNK (F) was also assessed. All values were normalized to GAPDH (housekeeping protein) detected on the same blots. Data are expressed as fold increase of control, mean 6 SEM. All challenges are compared with control, and challenges with poly(I:C) or LTA are compared with their respective challenge without poly(I:C) or LTA and challenge with poly(I:C) or LTA alone, using a one-way ANOVA (Fisher's least significant difference test). Significance is represented as *P , 0.05, **P , 0.01, ***P , 0.001, or ****P , 0.0001. Representative Western blots of phosphorylated and total p38 MAPK, NF-kB p65, and SAPK/JNK are shown under each graph. Figure 6 . Inhibition of cyclooxygenase (COX) or p38 MAPK suppresses cytokine release induced by AA alone and in combination with viral or bacterial surrogates from fibroblasts. Primary human pulmonary fibroblasts (n = 9-14) (patients) were treated with or without the COX inhibitor indomethacin (10 25 M), the p38 MAPK signaling inhibitor SB239063 (3 mM), the NF-kB inhibitor BAY-117082 (1 mM), or (A and B) the JNK inhibitor SP600125 (10 mM) for 60 minutes before challenge with AA (100 mM), (C and D) the viral mimic poly(I:C) (10 mg/ml), (E and F) AA (100 mM) in combination with poly(I:C), or (G and H) AA (100 mM) in combination with LTA (10 mg/ml). Cell-free supernatants were collected after 24 hours and (A, C, E, and G) IL-6 and (B, D, F, and H) CXCL8 release was measured using ELISA. All data are represented as percent cytokine release 6 SEM. All treatments with an inhibitor are compared with their respective control in the absence of the inhibitor using one-way ANOVA with a Bonferroni post test. Significance is represented as **P , 0.01, ***P , 0.001, or ****P , 0.0001. The human bronchial epithelial cell line BEAS-2B (n = 4-8) (replicates) was unstimulated or challenged with AA (100 mM), the viral mimic poly(I:C) (10 mg/ml), the bacterial compound LTA (10 mg/ml), AA (100 mM) in combination with poly(I:C) (1 ng/ml), or AA (100 mM) in combination with LTA for 30 minutes before whole-cell lysates were collected and p38 MAPK (A), NF-kB p65 (B), or SAPK/JNK (C) phosphorylation was assessed by Western blotting. (D-F) Total p38 MAPK (D), NF-kB p65 (E), or SAPK/JNK (F) was also assessed. All values were normalized to GAPDH (housekeeping protein) detected on the same blots. Data are expressed as fold increase of control, mean 6 SEM. All challenges are compared with control, and challenges with poly(I:C) or LTA are compared with their respective challenge without poly(I:C) or LTA and challenge with poly(I:C) or LTA alone, using a one-way ANOVA (Fisher's least significant difference test). Significance is represented as *P , 0.05. Representative Western blots of phosphorylated and total p38 MAPK, NF-kB p65, and SAPK/JNK are shown under each graph.
than either AA or RV16 alone in HPFs and BEAS-2Bs.
Less is known about bacterial infections in asthma. Some bacterial pathogens are more frequently found in the airways of patients with asthma than in healthy individuals (12) , but their role in exacerbations is unclear. Studies have reported mycoplasmal infection in up to 25% of children with wheezing (11) and in 20% of children with asthma requiring hospitalization due to exacerbations. However, not all studies have confirmed these findings (45). In the current study, we also investigated the effect of dietary fatty acids on bacterial infection. To model bacterial infection, we challenged cells with the bacterial endotoxin LTA. We found that challenge with AA in combination with LTA resulted in greater IL-6 and CXCL8 release from pulmonary fibroblasts and epithelial cells than either alone. The effect of the combination on cytokine release was substantially greater than the sum of the individual effects of AA and LTA, which indicates that these effects are synergistic. These results indicate that exposure to AA during bacterial infection may lead to more severe airway inflammation. There was no interaction between the other dietary fatty acids and LTA. Bacterial recognition is dependent on TLR2 and TLR4. TLR4 mainly senses LPS, which is a major component of the outer membrane of gram-negative bacteria. TLR2 is the primary innate immune receptor for grampositive bacteria. We used LTA, an important cell wall polymer found in grampositive bacteria that has been shown to cause innate immune responses mediated through TLR2 (46) . LTA alone, however, did not induce cytokine release from either HPFs or BEAS-2Bs. Presumably, even though bronchial epithelial cells express TLR2, challenge with LTA is not potent enough to induce the production of IL-6 or CXCL8 in epithelial cells, and a cochallenge is needed. Other studies have reported similar findings. Armstrong and colleagues found that LTA alone did not induce the production of CXCL8 or IL-6 in bronchial epithelial cells (47) , and a low responsiveness of lung epithelial cells to LTA (small increase in CXCL8 release) was observed in another in vitro study (48) .
The effects of dietary fatty acids on immune responses have been an area of interest for many years. However, there is a great deal of conflicting data. DHA and AA serve as important cell membrane components as well as precursors for biologic mediators with many effects, including numerous roles in immune function and inflammation. In general, v-6 PUFAs and SFAs have predominantly been associated with proinflammatory effects, whereas the v-3 PUFAs are associated with antiinflammatory and immunosuppressive effects (25, 34) . None of the v-3 PUFAs (DHA, EPA, and ALA) suppressed poly(I:C)-induced cytokine release, or combined AA and poly(I:C)-induced inflammatory responses in HPFs, suggesting that v-3 PUFAs do not have antiinflammatory effects in these lung cells. SFAs, including PA, initiate innate immune responses through activation of TLR2 and TLR4 in adipocytes and macrophages (24, 49, 50) . These results have been replicated in human studies, which showed that within 4 hours of consumption of a high-fat meal, innate immune responses were activated with increased TLR2, TLR4, and NF-kB activity in mononuclear and The human bronchial epithelial cell line BEAS-2B (n = 7) (replicates) was treated with or without the COX inhibitor indomethacin (10-5 M), the p38 MAPK signaling inhibitor SB239063 (3 mM), the NF-kB inhibitor BAY-117082 (1 mM), or (A and B) the JNK inhibitor SP600125 (10 mM) for 60 minutes before challenge with AA (100 mM) in combination with the viral mimic poly(I:C), (C and D) poly(I:C) alone, or (E and F) AA (100 mM) in combination with LTA (10 mg/ml). Cell-free supernatants were collected after 24 hours and (A, C, and E) IL-6 and (B, D, and F) CXCL8 release was measured using ELISA. All data are represented as percent cytokine release 6 SEM. All treatments with an inhibitor are compared with their respective control in the absence of the inhibitor using one-way ANOVA with a Bonferroni post test. Significance is represented as *P , 0.05, **P , 0.01, ***P , 0.001, or ****P , 0.0001.
polymorphonuclear cells (51, 52) . The nonresponsiveness to PA observed in this study may be explained by the lack of functional TLR4 signaling in pulmonary fibroblasts. Lung mesenchymal cells do not express CD14, which acts as a coreceptor for TLR4 (53, 54) . This is also why we used LTA (TLR2 agonist) and not LPS (TLR4 agonist). SFAs were previously shown to inhibit virus replication in a mouse model of chronic hepatitis B infection (55); however, another mouse model study showed that SFAs increase bacterial load in Staphylococcus aureus infection (56) . Studies looking at the effects of v-6 PUFAs on inflammatory processes and infections have reported conflicting data. A study in healthy men found that supplementation with v-6 PUFAs significantly increased the number of circulating neutrophils and production of LPS-induced leukotriene B4 from leukocytes (57) . Conversely, supplementation with AA did not affect in vitro secretion of TNF-a by peripheral mononuclear cells, nor did it affect peripheral blood mononuclear cell proliferation and natural killer cell activity. A study by Jordao and colleagues found that AA enhanced bacterial killing of Mycobacterium tuberculosis in macrophages, but increased pathogen survival in a mouse model of tuberculosis (58) . In the current study, a clear proinflammatory effect of AA on bacterial and viral infection was observed.
To understand the underlying mechanisms involved in (synergistic) AA and poly(I:C)-or LTA-induced IL-6 and CXCL8 production, signaling pathways were investigated. We observed activation of p38 MAPK upon challenge with AA alone and in combination with poly(I:C) or LTA. Challenge with poly(I:C) and LTA alone led to increased phosphorylation of NF-kB, while challenge with the combination of AA and poly(I:C) caused increased phosphorylation of SAPK/JNK. AA in combination with poly(I:C) led to greater phosphorylation of p38 MAPK than challenge with AA alone, indicating p38 MAPK signaling to be the mechanism by which synergism occurs. We further investigated and confirmed the underlying mechanisms involved in AA and poly(I:C)-or LTA-induced IL-6 and CXCL8 release using specific signaling inhibitors at concentrations previously shown to be effective in human airway cells (26) (27) (28) . SB239063 is a potent and selective inhibitor of p38 MAPK and displays specific and high-affinity binding (IC50 = 44 nM) (59) . It suppressed IL-6 and CXLC8 release induced by AA alone and the combinations of AA and poly(I:C) or LTA. These data suggest that AA in combination with poly(I:C) or LTA activates the p38 MAPK pathway, leading to both IL-6 and CXCL8 release. Inhibition of JNK with SP600125 suppressed IL-6 release induced by poly(I:C) alone and in combination with AA, but did not affect CXCL8 release. Inhibition of NF-kB with BAY-117082 partially suppressed IL-6 release induced by the combination of AA and LTA, again indicating the involvement of multiple pathways. These results, which showed that BAY-117082 suppressed AA and LTA-induced IL-6 but not CXCL8 release while SP600125 suppressed poly(I:C)-and AA/poly(I:C)-induced IL-6 but not CXCL8 release, are unexpected. Previous studies have shown IL-6 and CXCL8 transcription to be regulated by the same transcription factors: NF-kB, CREB protein, AP-1, and CCAAT/enhancer binding protein (C/EBP) (60, 61) . However, it appears that in this study the dominant transcription factors regulating CXCL8 are different to those regulating IL-6 with p38 MAPK being the only common transcription factor for both cytokines.
PGs, including PGE 2 , are COX metabolites of AA. PGE 2 induces IL-6 release from bronchial epithelial cells, and CXCL8 release from lung mesenchymal cells (62, 63) . To investigate whether COXmediated PGs contribute to IL-6 and CXCL8 release, we pretreated pulmonary fibroblasts with indomethacin, which inhibits both COX-1 and COX-2. Indomethacin inhibited AA-induced IL-6 and CXCL8 release alone and in combination with poly(I:C) or LTA. However, indomethacin did not affect cytokine release induced by poly(I:C) alone. Our data suggest that IL-6 and CXCL8 production in HPFs is PG mediated. We consider these effects to be mediated through COX-2 rather than COX-1, as COX-1 is responsible for constitutive production under basal conditions, whereas COX-2 is upregulated during inflammation and is responsible for PGE 2 biosynthesis at C D Figure 9 . Greater cytokine release was achieved with combined AA and human rhinovirus 16 (RV16) challenge than with either alone in human pulmonary fibroblasts and BEAS-2Bs. (A and B) Human primary pulmonary fibroblasts (n = 9) (patients) or (C and D) BEAS-2Bs (n = 7) (replicates) were unstimulated (control) or challenged with AA in 0.1% BSA-DMEM (100 mM) for 4 hours before infection with RV16 at a multiplicity of infection of 1 for another 24 hours. Cell-free supernatants were collected and (A and C) IL-6 and (B and D) CXCL8 release was measured using ELISA. All data are represented as mean 6 SEM. All challenges with RV16 are compared with their respective challenge without RV16 and with RV16 alone, using a one-way ANOVA with a Bonferroni post test. Significance is represented as *P , 0.05, **P , 0.01, or ***P , 0.001.
sites of inflammation (64) . We consider the combination of the production of COXmediated PGs and the activation of transcription factors to be the most logical mechanism for synergistic cytokine release in HPFs. We also investigated the underlying mechanisms in BEAS-2Bs and found that p38 MAPK signaling is involved in poly(I:C)-, combined poly(I:C) and AA-, and combined LTA and AA-induced IL-6 and CXCL8 release in BEAS-2Bs. However, inhibition of COX did not suppress IL-6 or CXCL8 release in BEAS-2Bs, which is different from what we observed in fibroblasts. This is consistent with the lack of cytokine induction by AA in BEAS-2B. In addition, inhibition of JNK signaling resulted in the greatest suppression of combined AA and poly(I:C)-or LTA-induced IL-6 and CXCL8 release in BEAS-2BS. These results suggest that there is a differential response in BEAS-2Bs compared with fibroblasts. Although we used primary HPFs here, an important limitation of this study is that all experiments were done in vitro. In future studies, we plan to investigate the effects of dietary fatty acids on immune responses to infection using an in vivo model. In summary, this study demonstrates that exposure of HPFs and epithelial cells to v-6 PUFAs causes an amplification of the inflammatory responses to viral and bacterial components, as measured by IL-6 and CXCL8 release. In HPFs the responses were PG dependent and mediated through p38 MAPK signaling, whereas the responses in BEAS-2Bs were mainly mediated through JNK and p38 MAPK signaling, suggesting that p38 MAPK inhibitors might be effective in obese patients with asthma to prevent exacerbations. In epithelial cells, exposure to PA also enhanced the inflammatory response to viral infection. These results suggest that during respiratory infection, increased levels of dietary v-6 PUFAs and SFAs may lead to more severe airway inflammation and might contribute to and/or increase the severity of asthma exacerbations in obese patients with asthma. n Author disclosures are available with the text of this article at www.atsjournals.org.
